Summary Cancer diagnostics is a strongly evolving field. Biovica’s novel cancer test can detect breast cancer progress cheaper and much faster than current methods. Biovica is the global leader in the field Its unprecedented 30 clinical trials in the prominent US and European hospitals minimize the risk of FDA failure. Biovica expects FDA approval andContinue reading “Biovica is one of the best peforming Scandinavian stocks, up 40% in 10 days. This should continue”
Time to GO BACK to scandinavian green and tech stock that sold off in Q2 – THE MACRO will drive repositioning.
When investing one thing to follow is macro. I follow Darius Dale for macro. Of all the research he is the most reliable. See 42macro.com. His recent position is: inflation is decelerating and will be decelerating further. This has several implications – the inflation linked assets are loosing steem. Commodities are decreasing – look atContinue reading “Time to GO BACK to scandinavian green and tech stock that sold off in Q2 – THE MACRO will drive repositioning.”
QUANTAFUEL Management is buying shares
In the last few days, Quantafuel managers reported the below transactions : 7/7/2021 – Kjetil Bøhn, Special Advisor in Quantafuel ASA, has today bought 20,000 shares in Quantafuel ASA through his wholly owned company KB Management AS, at a price of NOK 33.30 per share. After the transaction, Kjetil Bøhn and affiliates holds 3,677,050 sharesContinue reading “QUANTAFUEL Management is buying shares”
Minutes of the call with Quantafuel management today
I had an opportunity to join a call with Quantafuel management today. The participants were Dr Lach and the CFO Kristian Flatten: Dr. Lach joined Quantafuel from BASF this year. He did most of the talking. He is a brilliant mind, very smart and very knowledgeable. He comes out like a natural leader. He wouldContinue reading “Minutes of the call with Quantafuel management today”
Biovica International Should Double On Novel Breast Cancer Test Launch In Q3
Three months ago, I wrote an article for SA on Xbrane. I predicted a strong share price growth by the Phase 3 readout. Xbrane doubled. Biovica is a similar case. It should double in the next three months. For the same reasons as Xbrane did. Cancer diagnostics is a strongly evolving field. Biovica’s novel cancerContinue reading “Biovica International Should Double On Novel Breast Cancer Test Launch In Q3”
LInkfire IPO placed today – you are using Linkfire, if you are on Apple Music, Spotify, YouTube or most other music providers
The global market leading marketing platform for music labels and artists. I am long Linkfire. I think it is a case, that is worth to do some work on. They are the market leader and they will drive the industry consolidation. • Top major music labels use Linkfire with a combined market share of 70%Continue reading “LInkfire IPO placed today – you are using Linkfire, if you are on Apple Music, Spotify, YouTube or most other music providers”
NorsKe Skog – cheap vs peers, renewables activities for free
I wrote here several times about NSKOG. I am long and I like the story. It is cheap vs peers and its green itiatives at valued at zero. Pareto analyst believes the green intiatives have value equal to its mkt cap. It is cheap. And it is very cheap when paper prices are raising asContinue reading “NorsKe Skog – cheap vs peers, renewables activities for free”
Elegant way to protect Scandi portfolio against downturn
Friday was bloody. The markets are quite high and becomming fragile. I wrote here about many long ideas, that I played. I have been torturing myself how to hedge against violent downturn. I am looking at short ideas, that are short based on its fundamentals – that will go down it good or bad markets.Continue reading “Elegant way to protect Scandi portfolio against downturn”
Biovica should double by the start of commercial launch in today confirmed Q3
Today Biovica International published its annual results. There are important quotes in the CEO comments that investors should focus on: “We are following our schedule for being able to launch DiviTum®TKa in the USA during the third quarter 2021 and utilizing the time prior to approval in the best way possible.” “Our application is oneContinue reading “Biovica should double by the start of commercial launch in today confirmed Q3”
Biovica – FDA approval in Q3, commercionalisation in Q4
In mid April 2021 I wrote about XBrane for the first time. At that time Xbrane was trading around 78 SEK, it is 170 SEK today. The reason for the share price growth was the imminent announcement of Phase 3 results and very high likelihood of positive outcome (97% for biosimilars). These shares always perform well priorContinue reading “Biovica – FDA approval in Q3, commercionalisation in Q4”